Halozyme Therapeutics Inc [HALO] stock prices are down -3.05% to $57.54 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The HALO shares have lost -7.00% over the last week, with a monthly amount drifted -6.35%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Halozyme Therapeutics Inc [NASDAQ: HALO] stock has seen the most recent analyst activity on October 07, 2024, when Wells Fargo downgraded its rating to a Equal Weight and also boosted its price target to $62 from $58. Previously, JP Morgan downgraded its rating to Neutral on September 19, 2024, and elevated its price target to $57. On June 07, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $51 on the stock. TD Cowen started tracking the stock assigning a Outperform rating and suggested a price target of $54 on February 29, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $61 as its price target on July 24, 2023. Goldman downgraded its rating to Neutral for this stock on July 24, 2023, and upped its price target to $45. In a note dated May 10, 2023, Piper Sandler upgraded an Overweight rating on this stock but restated the target price of $46.
The stock price of Halozyme Therapeutics Inc [HALO] has been fluctuating between $37.73 and $66.00 over the past year. Currently, Wall Street analysts expect the stock to reach $52 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $57.54 at the most recent close of the market. An investor can expect a potential drop of -9.63% based on the average HALO price forecast.
Analyzing the HALO fundamentals
The Halozyme Therapeutics Inc [NASDAQ:HALO] reported sales of 1.02B for trailing twelve months, representing a surge of 29.55%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at 0.54%, Pretax Profit Margin comes in at 0.55%, and Net Profit Margin reading is 0.44%. To continue investigating profitability, this company’s Return on Assets is posted at 0.22, Equity is 1.38 and Total Capital is 0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 4.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.86 points at the first support level, and at 54.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 60.30, and for the 2nd resistance point, it is at 63.05.
Ratios To Look Out For
It’s worth pointing out that Halozyme Therapeutics Inc [NASDAQ:HALO]’s Current Ratio is 7.80. In addition, the Quick Ratio stands at 6.78 and the Cash Ratio stands at 0.83. Considering the valuation of this stock, the price to sales ratio is 7.00, the price to book ratio is 19.47 and price to earnings (TTM) ratio is 16.76.
Transactions by insiders
Recent insider trading involved Henderson Jeffrey William, Director, that happened on Apr 01 ’25 when 503.0 shares were sold. Director, Henderson Jeffrey William completed a deal on Mar 03 ’25 to sell 5000.0 shares. Meanwhile, SVP, CHIEF TECHNICAL OFFICER LaBarre Michael J. sold 10000.0 shares on Feb 26 ’25.
